Literature DB >> 22994439

Risk score model for predicting mortality in advanced heart failure patients followed in a heart failure clinic.

Barak Zafrir1, Yaron Goren, Hagar Paz, Rafael Wolff, Nabia Salman, Dina Merhavi, Idit Lavi, Basil S Lewis, Offer Amir.   

Abstract

The prevalence of heart failure (HF) in the population is increasing, concomitant with high incidence of rehospitalizations and mortality. The aim of this study was to characterize a prognostic risk score model for patients with chronic HF. A total of 500 patients followed at the HF clinic were evaluated by clinical, functional, laboratory, imaging, and therapeutic variables that were correlated to mortality during a follow-up period of 25 months. Risk stratification was carried out by applying a risk score model based on multivariate analysis. Predictors correlated with mortality during follow-up were systolic blood pressure <110 mm Hg, male sex, age older than 70 years, 6-minute walk distance <300 m, lack of β-blocker therapy, hyperuricemia (>7.5 mg/dL), hyponatremia, and prolonged QTc interval (>450 ms). Based on these variables, a risk score model (score 0-55) was established and included low risk, score <21 (9% mortality during 2-year follow-up); moderate risk, 21 to 29 (22%); high risk, 30 to 35 (35%), and very high risk: ≥36 points (62% 2-year mortality). The risk model had good discrimination ability (concordance index 0.75), which was better than the performance of the Seattle Heart Failure Model on our cohort (0.69). Simple noninvasive characteristics examined during the initial admission to the HF clinic can serve as prognostic markers for mortality and may help in the process of therapeutic decision-making in patients with HF.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22994439     DOI: 10.1111/j.1751-7133.2012.00286.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


  6 in total

1.  High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) Registry.

Authors:  Amrut V Ambardekar; Rhondalyn C Forde-McLean; Michelle M Kittleson; Garrick C Stewart; Maryse Palardy; Jennifer T Thibodeau; Adam D DeVore; Maria M Mountis; Linda Cadaret; Jeffrey J Teuteberg; Salpy V Pamboukian; Ryan S Cantor; JoAnn Lindenfeld
Journal:  J Heart Lung Transplant       Date:  2016-01-18       Impact factor: 10.247

Review 2.  Mitral Valve Clip for Treatment of Mitral Regurgitation: An Evidence-Based Analysis.

Authors:  Mohammed T Ansari; Nadera Ahmadzai; Kathryn Coyle; Doug Coyle; David Moher
Journal:  Ont Health Technol Assess Ser       Date:  2015-05-01

3.  INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: A report from the REVIVAL Registry.

Authors:  Michelle M Kittleson; Palak Shah; Anuradha Lala; Rhondalyn C McLean; Salpy Pamboukian; Douglas A Horstmanshof; Jennifer Thibodeau; Keyur Shah; Jeffrey Teuteberg; Nisha A Gilotra; Wendy C Taddei-Peters; Thomas M Cascino; Blair Richards; Shokoufeh Khalatbari; Neal Jeffries; Lynne W Stevenson; Douglas Mann; Keith D Aaronson; Garrick C Stewart
Journal:  J Heart Lung Transplant       Date:  2019-08-28       Impact factor: 10.247

4.  Risk factors for incident hyperuricemia during mid-adulthood in African American and white men and women enrolled in the ARIC cohort study.

Authors:  Mara A McAdams-DeMarco; Andrew Law; Janet W Maynard; Josef Coresh; Alan N Baer
Journal:  BMC Musculoskelet Disord       Date:  2013-12-11       Impact factor: 2.362

5.  Prognostic impact of 6 min walk test distance in patients with systolic heart failure: insights from the WARCEF trial.

Authors:  Kenji Matsumoto; Yi Xiao; Shunichi Homma; John L P Thompson; Richard Buchsbaum; Kazato Ito; Stefan D Anker; Min Qian; Marco R Di Tullio
Journal:  ESC Heart Fail       Date:  2020-12-30

6.  Mitral peak early diastolic filling velocity to deceleration time ratio as a predictor of prognosis in patients with chronic heart failure and preserved or reduced ejection fraction.

Authors:  Flora Pirozzi; Antonella Paglia; Laura Sasso; Pasquale Abete; Angelo Carlomagno; Carlo G Tocchetti; Domenico Bonaduce; Mario Petretta
Journal:  J Geriatr Cardiol       Date:  2015-07       Impact factor: 3.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.